About Omniseq

About company

OmniSeq offers physicians and their patients of the most actionable tumor-profiling information possible. OmniSeq, an innovation of Roswell Park Cancer Institute, is a molecular diagnostic laboratory. It endeavors to find the right drug or the right trial for every patient. It also offers NY State CLEP approved assays, including OmniSeq Comprehensive, a 144 gene NGS assay that covers almost all known genetic alterations associated with an FDA-approved targeted therapy or genotype directed clinical trial. OmniSeq is also making significant investments to create better diagnostics for immuno-oncology therapy selection. The company was founded in 2015 and is based in Buffalo, New York.